Mathias-300x400-225x300

IR contact

Dr. Mathias Svahn, CEO

Leo Groenewegen, CFO

Phone: +46 (0)8-735 5595

Email: info@nextcellpharma.com

 

Reports


 


Please contact CEO Dr. Mathias Svahn for an investor pack and other information.

mathias.svahn@nextcellpharma.com

Financial calendar 2018

Q1 report


31 January 2018

Q3 report


31 July 2018

Q2 report


30 April 2018

Bokslutskommuniké


October 31th 2018

Financial calendar 2017

Interim Report


31 July 2017

Year-End Report


31 October 2017

Annual Report


14 November 2017

Annual General Meeting


Planned for December 5th 2017

Share information

Dividend

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development. There is a risk that future cash flows will not exceed the company’s capital requirements and that future AGMs will not decide on future dividends.

Transparency

Shares in NextCell Pharma AB are traded on Aktietorget as per July 2017.

List of 5 largest shareholders as per 2017-12-30 (as per the aktiebok)

Owners Number of shares Ownership (%)
Diamyd Medical AB* 1 175 291 13,8
Avanza Pension 979 520 11,52
Anders Essen-Möller** 562 033 6,61
MabTech Group AB 291 216 3,42
Nordnet Pensionsförsäkring 221 088 2,60
Other owners 4 915 419 62,56
   
Total 8 144 567 100.00

 

* NextCell’s Board Chairman Anders Essen-Möller owns 16.8% of the shares and 40.1% of the votes in Diamyd Medical AB.

** Anders Essen-Möller is the Board Chairman of NextCell.

Share price

NextCell Pharma AB has stock units worth MSEK 17 with associated free-of-charge warrants. A unit comprises 5 shares and 4 warrants. The subscription period was 24 May to 12 June 2017. The current share price is available on Aktietorget.

https://ir.aktietorget.se/company/overview/?id=456&InstrumentID=SE0009723125

Corporate governance

Committee


There is no information to enter under this point

Auditor


Bo Åsell

Öhrlings PricewaterhouseCoopers AB (PwC)
Torsgatan 21, 113 97 Stockholm

Bo Åsell is an Authorized Public Accountant and a member of FAR, the institute for the accountancy profession in Sweden.

Nomination Committee


No information available

Articles of Association


Incentive programmes


NextCell Pharma AB currently has no active incentive programmes.

IPO

 Registration form


NextCell Pharma - Anmälningssedel

 

Instruction for subscription registration


Instructions are included in the subscription form. 

AktieTorget

NextCell Pharma AB is listed on the AktieTorget stock exchange since July 2017.

Link to aktietorget

Link to NextCell's IR page on Aktietorget